Management Change/Compensation (Form 8-K)

Departure of Chief Financial Officer

On April 28, 2026, the Board of Directors (the "Board") of Damora Therapeutics, Inc. (the "Company") determined that, effective as of May 1, 2026 (the "Effective Time"), Lori Firmani would cease serving as the Company's Chief Financial Officer. Ms. Firmani had served as the Company's principal financial officer and principal accounting officer since August 2024, prior to the Company's acquisition of privately-held Damora Therapeutics, Inc. in November 2025. Subject to Ms. Firmani's execution and non-revocation of a separation agreement and general release of claims in favor of the Company in a form agreed to by the Company, Ms. Firmani will be entitled to receive separation benefits in accordance with the Company's Executive Separation Benefits Plan, as described in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2026 (the "Proxy Statement"); however, the base salary continuation and pro-rated target bonus will be paid in a single lump sum, Ms. Firmani will receive a health savings account contribution of $6,000, and all of Ms. Firmani's outstanding equity awards will be fully accelerated.

Appointment of Principal Financial Officer and Principal Accounting Officer

On April 28, 2026, the Board appointed Brian Burkavage, the Company's current Senior Vice President, Finance, to serve as the Company's principal financial officer and principal accounting officer, effective as of the Effective Time.

Brian Burkavage, age 43. Prior to joining the Company in December 2025, Mr. Burkavage served as Senior Vice President, Finance and Chief Accounting Officer and VP, Finance at IO Biotech, Inc. from November 2021 to December 2025. Prior to that, he served as the Controller at Passage Bio, Inc. from 2020 to 2021, and Director of Financial Planning and Analysis at Aclaris Therapeutics, Inc. from 2017 to 2020. Earlier in his career, he spent 11 years at Ernst & Young LLP in roles of increasing responsibility within the financial statement audit practice. Mr. Burkavage earned his B.A. and M.S.A. from the University of Notre Dame and is a licensed Certified Public Accountant.

Mr. Burkavage was not appointed pursuant to any arrangement or understanding between him and any other person. Mr. Burkavage does not have any family relationships with any director or executive officer of the Company, and there are no transactions in which Mr. Burkavage has a direct or indirect material interest requiring disclosure under Item 404(a) of Regulation S-K.

In connection with his appointment as an officer, Mr. Burkavage will enter into the Company's standard form of indemnification agreement for its executive officers, a copy which was filed as Exhibit 10.4 to the Company's Amended Registration Statement on Form S-1/A (File No. 333-249369) filed with the Securities and Exchange Commission on October 22, 2020.